# COL5A1

## Overview
The COL5A1 gene encodes the collagen type V alpha 1 chain, a crucial component of type V collagen, which is a minor fibrillar collagen involved in the formation and regulation of collagen fibrils within the extracellular matrix (ECM) of connective tissues. The protein encoded by COL5A1 plays a significant role in the nucleation and regulation of collagen fibril diameter, particularly through its interaction with type I collagen to form heterotypic fibrils. This interaction is essential for maintaining the structural integrity and mechanical properties of various tissues, including the corneal stroma, bone matrix, and interstitial matrices of muscles and organs. The regulation of fibril assembly by type V collagen is mediated through its NH2-terminal domain, which controls fibril diameter and density, ensuring proper collagen fibrillogenesis. Mutations in COL5A1 are associated with classic Ehlers-Danlos Syndrome, a connective tissue disorder, and its expression levels have been implicated in the progression of certain cancers, highlighting its clinical significance (Chen2024COL5A1; Birk2001Type; Symoens2010Identification).

## Structure
The COL5A1 gene encodes the pro-alpha 1(V) collagen chain, a component of type V collagen, which is a fibrillar collagen involved in the formation of the extracellular matrix. The primary structure of the pro-alpha 1(V) chain includes a signal peptide, a large NH2-terminal noncollagenous region, a main collagenous region, and a COOH-terminal noncollagenous region. The main collagenous region consists of 338 Gly-X-Y triplet repeats, where X and Y are often proline and hydroxyproline, forming a triple helix structure (Takahara1991Complete; Greenspan1991The).

The NH2-terminal noncollagenous region is larger than those of other collagens and contains a region homologous to the COOH-terminal domain of laminin A chain, but lacks a cysteine-rich region. It also includes probable tyrosine sulfation sites and short collagenous sequences interrupted by noncollagenous segments (Takahara1991Complete). The COOH-terminal noncollagenous region contains cysteine residues important for triple helix formation (Takahara1991Complete).

Type V collagen typically associates with type I collagen to form heterotypic fibrils, contributing to the quaternary structure. This association is crucial for regulating the diameter of collagen fibrils (Symoens2008COL5A1). Post-translational modifications of the pro-alpha 1(V) chain include hydroxylation and glycosylation, which are common in collagen proteins (Greenspan1991The).

## Function
The COL5A1 gene encodes the alpha-1 chain of type V collagen, a minor fibrillar collagen that plays a crucial role in the formation and regulation of collagen fibrils in the extracellular matrix (ECM) of connective tissues. In healthy human cells, type V collagen is essential for the nucleation and regulation of collagen fibril diameter, particularly in the formation of heterotypic fibrils with type I collagen. This interaction is vital for maintaining the structural integrity and mechanical properties of tissues such as the corneal stroma, bone matrix, and interstitial matrices of muscles, liver, lungs, and placenta (Leeming2019Type; Birk2001Type; Symoens2010Identification).

Type V collagen, through its NH2-terminal domain, regulates fibril assembly by controlling fibril diameter and density, which is crucial for proper collagen fibrillogenesis. This regulation ensures the correct formation and maintenance of collagen fibrils, contributing to the strength and flexibility of connective tissues (Birk2001Type; Symoens2008COL5A1). The α1(V)-N-propeptide of type V collagen extends from the surface of heterotypic type I/V collagen fibrils, interacting with various binding partners and playing a role in maintaining normal collagen fibrillogenesis (Symoens2010Identification).

## Clinical Significance
Mutations and alterations in the COL5A1 gene are associated with several clinical conditions, most notably classic Ehlers-Danlos Syndrome (EDS). This heritable connective tissue disorder is characterized by skin hyperextensibility, joint hypermobility, and tissue fragility. Mutations in COL5A1 often result in a non-functional allele, leading to haploinsufficiency, which is a common molecular mechanism underlying classic EDS. This haploinsufficiency affects the normal formation of collagen fibrils, contributing to the clinical manifestations of the syndrome (Wenstrup2000COL5A1; Malfait2004The). Specific mutations, such as those in the signal peptide region, can interfere with protein secretion, further contributing to the pathogenesis of EDS (Symoens2008COL5A1).

In addition to EDS, alterations in COL5A1 expression have been implicated in various cancers. In tongue squamous cell carcinoma (TSCC), high COL5A1 expression is associated with advanced pathological stages and poor prognosis, making it an unfavorable prognostic marker (Chen2019Differential). Similarly, in gliomas, overexpression of COL5A1 correlates with higher tumor grades and poor prognosis, suggesting its potential as a therapeutic target (Gu2021COL5A1). These findings highlight the diverse clinical significance of COL5A1 in both genetic disorders and cancer.

## Interactions
The COL5A1 gene encodes the alpha-1 chain of type V collagen, which plays a significant role in collagen fibrillogenesis and interacts with various proteins in the extracellular matrix (ECM). The α1(V)-N-propeptide of type V collagen is known to interact with several ECM proteins, including types I and VI collagen, fibronectin, tenascin C, and procollagen C-proteinase enhancer-1 (PCPE-1). These interactions are crucial for matrix assembly and cell-matrix interactions (Symoens2010Identification).

The α1(V)-N-propeptide also binds to matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), which are involved in ECM remodeling. Transforming growth factor-β1 (TGF-β1) is another binding partner, suggesting a complex relationship between TGF-β1 signaling and ECM assembly (Symoens2010Identification).

In the context of cancer, COL5A1 interacts with tumor-associated macrophages (TAMs) in triple-negative breast cancer (TNBC), promoting chemoresistance through the JAK2/STAT3 signaling pathway. It also interacts with transglutaminase 2 (TGM2), inhibiting its degradation and contributing to increased chemoresistance and IL-6 secretion (Chen2024COL5A1). These interactions highlight the multifaceted role of COL5A1 in both normal physiological processes and disease states.


## References


[1. (Leeming2019Type) D.J. Leeming and M.A. Karsdal. Type V collagen, pages 51–57. Elsevier, 2019. URL: http://dx.doi.org/10.1016/b978-0-12-817068-7.00005-7, doi:10.1016/b978-0-12-817068-7.00005-7. This article has 6 citations.](https://doi.org/10.1016/b978-0-12-817068-7.00005-7)

[2. (Wenstrup2000COL5A1) Richard J. Wenstrup, Jane B. Florer, Marcia C. Willing, Cecilia Giunta, Beat Steinmann, Felix Young, Miki Susic, and William G. Cole. Col5a1 haploinsufficiency is a common molecular mechanism underlying the classical form of eds. The American Journal of Human Genetics, 66(6):1766–1776, June 2000. URL: http://dx.doi.org/10.1086/302930, doi:10.1086/302930. This article has 101 citations.](https://doi.org/10.1086/302930)

[3. (Gu2021COL5A1) Sujie Gu, Zesheng Peng, Yuxi Wu, Yihao Wang, Deqiang Lei, Xiaobing Jiang, Hongyang Zhao, and Peng Fu. Col5a1 serves as a biomarker of tumor progression and poor prognosis and may be a potential therapeutic target in gliomas. Frontiers in Oncology, November 2021. URL: http://dx.doi.org/10.3389/fonc.2021.752694, doi:10.3389/fonc.2021.752694. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.752694)

[4. (Symoens2010Identification) Sofie Symoens, Marjolijn Renard, Christelle Bonod-Bidaud, Delfien Syx, Elisabeth Vaganay, Fransiska Malfait, Sylvie Ricard-Blum, Efrat Kessler, Lut Van Laer, Paul Coucke, Florence Ruggiero, and Anne De Paepe. Identification of binding partners interacting with the α1-n-propeptide of type v collagen. Biochemical Journal, 433(2):371–381, December 2010. URL: http://dx.doi.org/10.1042/bj20101061, doi:10.1042/bj20101061. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20101061)

[5. (Takahara1991Complete) K. Takahara, Y. Sato, K. Okazawa, N. Okamoto, A. Noda, Y. Yaoi, and I. Kato. Complete primary structure of human collagen alpha 1 (v) chain. Journal of Biological Chemistry, 266(20):13124–13129, July 1991. URL: http://dx.doi.org/10.1016/s0021-9258(18)98813-7, doi:10.1016/s0021-9258(18)98813-7. This article has 74 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)98813-7)

[6. (Birk2001Type) D.E Birk. Type v collagen: heterotypic type i/v collagen interactions in the regulation of fibril assembly. Micron, 32(3):223–237, April 2001. URL: http://dx.doi.org/10.1016/s0968-4328(00)00043-3, doi:10.1016/s0968-4328(00)00043-3. This article has 319 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0968-4328(00)00043-3)

[7. (Greenspan1991The) D.S. Greenspan, W. Cheng, and G.G. Hoffman. The pro-alpha 1(v) collagen chain. complete primary structure, distribution of expression, and comparison with the pro-alpha 1(xi) collagen chain. Journal of Biological Chemistry, 266(36):24727–24733, December 1991. URL: http://dx.doi.org/10.1016/s0021-9258(18)54290-3, doi:10.1016/s0021-9258(18)54290-3. This article has 67 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)54290-3)

[8. (Chen2019Differential) Hung‐Chih Chen, Yu‐Kai Tseng, Chih‐Wen Shu, Ta‐Jung Weng, Huei‐Han Liou, Liang‐Ming Yen, I‐Chien Hsieh, Cheng‐Ching Wang, Pi‐Chuan Wu, Yow‐Ling Shiue, Ting‐Ying Fu, Kuo‐Wang Tsai, Luo‐Ping Ger, and Pei‐Feng Liu. Differential clinical significance of <scp>col</scp>5a1 and <scp>col</scp>5a2 in tongue squamous cell carcinoma. Journal of Oral Pathology &amp; Medicine, 48(6):468–476, April 2019. URL: http://dx.doi.org/10.1111/jop.12861, doi:10.1111/jop.12861. This article has 16 citations.](https://doi.org/10.1111/jop.12861)

[9. (Chen2024COL5A1) Xi Chen, Chenao Ma, Yaming Li, Yiran Liang, Tong Chen, Dianwen Han, Dan Luo, Ning Zhang, Wenjing Zhao, Lijuan Wang, and Qifeng Yang. Col5a1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk. Oncogene, 43(23):1742–1756, April 2024. URL: http://dx.doi.org/10.1038/s41388-024-03030-3, doi:10.1038/s41388-024-03030-3. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-024-03030-3)

[10. (Malfait2004The) Fransiska Malfait, Paul Coucke, Sofie Symoens, Bart Loeys, Lieve Nuytinck, and Anne De Paepe. The molecular basis of classic ehlers-danlos syndrome: a comprehensive study of biochemical and molecular findings in 48 unrelated patients. Human Mutation, 25(1):28–37, 2004. URL: http://dx.doi.org/10.1002/humu.20107, doi:10.1002/humu.20107. This article has 105 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20107)

[11. (Symoens2008COL5A1) Sofie Symoens, Fransiska Malfait, Marjolijn Renard, Josette André, Ingrid Hausser, Bart Loeys, Paul Coucke, and Anne De Paepe. Col5a1 signal peptide mutations interfere with protein secretion and cause classic ehlers-danlos syndrome: mutations in brief. Human Mutation, 30(2):E395–E403, October 2008. URL: http://dx.doi.org/10.1002/humu.20887, doi:10.1002/humu.20887. This article has 53 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20887)